Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
Más filtros












Base de datos
Intervalo de año de publicación
1.
Vaccine ; 24(16): 3203-16, 2006 Apr 12.
Artículo en Inglés | MEDLINE | ID: mdl-16480795

RESUMEN

Therapeutic vaccination with dendritic cells presenting tumor-specific antigens is now recognized as an important investigational therapy for the treatment of neoplastic disease. Dendritic cell cross-presentation is credited with the ability of tumor lysate-loaded dendritic cells to prime both CD4 and CD8-specific T-lymphocyte responses, enabling the generation of cancer specific CTL activity without the loading of the classical MHC class I compartment. Recently, however, several reports have raised doubts as to the efficiency of cross-presentation as a mechanism for CTL priming in vivo. To examine this issue, we have doubly-loaded human dendritic cells with both AML-specific tumor lysate and AML-specific tumor mRNA. Our results show that these doubly-loaded dendritic cells can mediate superior primary, recall, and effector lytic responses in vitro in comparison to those of dendritic cells loaded with either tumor lysate or tumor mRNA alone. Enhanced recall responses appeared to be influenced by CD40/CD40L signaling, underscoring the importance of T-cell help in the generation and perpetuation of the adaptive immune response.


Asunto(s)
Antígenos de Neoplasias/inmunología , Células Dendríticas/inmunología , Leucemia Mieloide Aguda/inmunología , ARN Mensajero/inmunología , Linfocitos T/inmunología , Antígenos de Neoplasias/metabolismo , Ligando de CD40/inmunología , Linfocitos T CD8-positivos/inmunología , Células Cultivadas , Citotoxicidad Inmunológica , Humanos , Memoria Inmunológica , Interferón gamma/biosíntesis , Activación de Linfocitos , Subgrupos Linfocitarios/inmunología , ARN Mensajero/metabolismo
2.
Circulation ; 111(14): 1833-40, 2005 Apr 12.
Artículo en Inglés | MEDLINE | ID: mdl-15824211

RESUMEN

BACKGROUND: Cyclooxygenase-1 (COX-1) is the rate-limiting component in the synthesis of prostacyclin (PGI2), an important vasodilator and antithrombotic molecule. In balloon-injured, atherosclerosis-free porcine arteries, COX-1 gene transduction increases PGI2 production, induces durable vasodilation, and reduces thrombus formation. We tested the effectiveness of COX-1 local gene transduction for the prevention of postangioplasty restenosis in atherosclerotic arteries in a hypercholesterolemic rabbit model. METHODS AND RESULTS: We injured 1 carotid artery in 43 Watanabe heritable hyperlipidemic rabbits and performed local gene transduction using a viral vector containing the COX-1 gene (AdCOX-1, n=22) or no genes (Adnull, n=21). Three days later, AdCOX-1-treated arteries stimulated with arachidonic acid produced 100% more PGI2 (P<0.01), 400% more prostaglandin E2 (PGE2) (P<0.01), 400% more prostaglandin E1 (PGE1) (P<0.01), and 250% more cAMP (P<0.05) than Adnull-treated arteries. Twenty-eight days after treatment, Doppler sonography showed that blood flow velocity was preserved in AdCOX-1-treated arteries (ratio 0.92, injured compared with contralateral uninjured carotid artery) but reduced in Adnull-treated arteries (ratio 0.39), suggesting that AdCOX-1 prevented restenosis after injury. COX-1-transduced arteries also showed 80% greater lumen area 28 days after injury (P<0.01). CONCLUSIONS: The effectiveness of COX-1 in preventing restenosis and preserving normal blood flow 28 days after injury results from increased lumen area caused by durable vasodilation. COX-1 efficacy correlates with an early increase in the production of PGI2, PGE2, PGE1 (known to cause vasodilation), and cAMP. These results demonstrate for the first time that COX-1 gene transduction is an effective treatment for the prevention of postangioplasty restenosis of atherosclerotic arteries under clinically relevant conditions.


Asunto(s)
Angioplastia de Balón/efectos adversos , Arteriosclerosis/tratamiento farmacológico , Traumatismos de las Arterias Carótidas/tratamiento farmacológico , Prostaglandina-Endoperóxido Sintasas/farmacología , Flujo Sanguíneo Regional/efectos de los fármacos , Animales , Estenosis Carotídea/prevención & control , AMP Cíclico/biosíntesis , Ciclooxigenasa 1 , Terapia Genética/métodos , Prostaglandina-Endoperóxido Sintasas/administración & dosificación , Prostaglandina-Endoperóxido Sintasas/genética , Prostaglandinas/biosíntesis , Conejos , Transducción Genética/métodos , Regulación hacia Arriba/efectos de los fármacos
3.
Mol Ther ; 8(1): 118-29, 2003 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-12842435

RESUMEN

Replication-competent lentivirus (RCL) may be generated during the production phase or subsequently after introduction of a lentiviral vector into target cells, potentially by homologous or nonhomologous recombination. Because most gene transfer of HIV-based vectors involves the use of high-titer vesicular stomatitis virus (VSV) G-pseudotyped particles, one particular concern would be the generation of an RCL of altered host range, i.e., one that has incorporated the VSV G envelope in cis configuration. We report here on the artificial generation and properties of such a virus, including its detection after biological amplification. Viral spread, beginning with a very low inoculum, takes several weeks in culture and is characterized by "autoinfection," resulting in multiple proviral copies per cell, higher levels of viral gene expression, and eventual cell death. After this initial amplification step, the RCL is easily detectable by standard p24 assay or by "marker-rescue" assay. For the latter, a 293T-based cell line that has an integrated replication-defective provirus encoding alkaline phosphatase (AP) was used and mobilization of AP-containing virus was detected by transduction of naïve cells. Replication-defective virus was not amplified nor detected, demonstrating assay specificity. These results suggest that these artificial RCLs of broad host range have slightly different biological properties compared to wild-type HIV but still spread and are readily detectable.


Asunto(s)
Lentivirus/genética , Fosfatasa Alcalina/metabolismo , Línea Celular , Citometría de Flujo , Técnicas de Transferencia de Gen , Marcadores Genéticos , Terapia Genética/métodos , Vectores Genéticos , Humanos , Modelos Genéticos , Plásmidos/metabolismo , Reacción en Cadena de la Polimerasa , Recombinación Genética , Factores de Tiempo , Transducción Genética , Virus de la Estomatitis Vesicular Indiana/genética , Replicación Viral
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...